SHPH · Shuttle Pharmaceuticals Holdings, Inc.

This 8-K documents a transformative strategic shift for Shuttle Pharmaceuticals Holdings, Inc., centered on the completed acquisition of United Dogecoin Inc.—a company with leadership rooted in cryptocurrency and digital asset ventures—marking a material pivot toward blockchain-integrated pharmaceutical development or commercial infrastructure. The transaction was executed via merger, with United Dogecoin surviving as a wholly owned subsidiary, and funded through a multi-layered capital structure: 8,403 shares of Series B-1 Preferred Stock issued directly to former United Dogecoin stockholders, plus a $9.55 million PIPE financing that delivered Series B-2 Preferred Stock and warrants. Critically, both preferred series are convertible only upon receipt of stockholder approval, introducing near-term governance risk and execution dependency. The appointment of Ryan Trasolini—a founder and CEO of United Dogecoin since December 2025 and previously involved in US Bitcoin Corporation and Sesh Products—as Co-CEO signals deep operational integration and likely strategic reorientation, though his lack of a formal employment agreement introduces leadership continuity uncertainty. Concurrently, the Second Amendment to the Asset Purchase Agreement reflects ongoing obligations under a separate Canadian transaction, adding $3.65 million in cash and additional preferred stock to the capital outflow. Collectively, these actions materially alter Shuttle’s corporate profile, equity structure, and strategic direction—introducing new technology exposure, significant dilution risk pending approvals, and governance dependencies—all without disclosure of financial performance, revenue synergies, or clinical or commercial milestones tied to the acquired entity. Investors must assess whether the blockchain-aligned leadership and capital structure align with Shuttle’s prior pharmaceutical focus or represent a de facto change in business model.